Eisai will use MultiCell’s technologies for drug discovery and ADME-Tox applications.
MultiCell Technologies granted Eisia a five-year nonexclusive license to aid in its drug discovery program. Eisai will use MultiCell’s Fa2N-4 immortalized human hepatocyte cells and MFE™ culture media for discovery and ADME-Tox applications at its Tsukuba Research Laboratories in Japan.
“Eisai has been using our Fa2N-4 cells and culture media for several years under a sublicense agreement granted by XenoTech LLC, our previous licensee,” points out ,” points out Stephen Chang, president and CEO of Multicell.
“Our new, direct agreement with Eisai is another validation of the value of our proprietary immortalized cell lines for drug discovery/ADME-Tox applications.”
